proteomic biomarker search requires the greatest analytical reproducibility and detailed information on altered proteoforms. our protein pre-fractionation applies orthogonal native chromatography and conserves important features of protein variants such as native molecular weight, charge and major glycans. Moreover, we maximized reproducibility of sample pre-fractionation and preparation before mass spectrometry by parallelization and automation. In blood plasma and cerebrospinal fluid (cSf), most proteins, including candidate biomarkers, distribute into a multitude of chromatographic clusters. Plasma albumin, for example, divides into 15-17 clusters. As an example of our technique, we analyzed these albumin clusters from healthy volunteers and from dogs and identified cluster-typical modification patterns. Renal disease further modifies these patterns. In human CSF, we found only a subset of proteoforms with fewer modifications than in plasma. We infer from this example that our method can be used to identify and characterize distinct proteoforms and, optionally, enrich them, thereby yielding the characteristics of proteoform-selective biomarkers. Figure 5 . Dependence of the degree of PTM (n PTM/PSM) on the concentration of NaCl required for the elution of albumin from AEC matrix. Filled symbols: healthy plasma volunteers and healthy dogs; open symbols: plasma from patients with ESRD and dogs affected by preclinical Alport syndrome. Sub-fractions from plasma pools: orange squares, sub-fractions derived from albumin centric 1D (human plasma: 1D 67, dog plasma: 1D 23); turquoise triangles, sub-fractions derived from LMW albumin (1D 71); blue diamonds, sub-fractions derived from high Mw albumin (1D 63); black circles, sub-fractions from human CSF albumin, centric 1D 23. Data of human plasma were combined from individually pre-fractionated, prepared and analyzed samples from two healthy male volunteers (multi reports from four runs) and from four patients under hemodialysis (multi reports from eight runs). Due to slightly different pooling of the 2D-fractions, data from healthy male and female volunteers were not combined. Results from healthy female volunteers are similar to those from male volunteers and are shown in Supplementary Fig. 8 . Accordingly, data from human CSF represent multi reports of nine runs (three sample pools analyzed in triplicate) and data from dog serum are means of technical duplicates from two sample pools. Ordinates: number of affected sites of the modification per PSM (n PTM/PSM) Abscissas: Concentration of NaCl (mM) required for elution of the subfraction from the AEC matrix (cf. Fig. 4c ). R 2 is given in the same color as and near to the corresponding data points.
A major challenge in the search for proteomic biomarkers is the low reproducibility among studies. There are several likely reasons for this low reproducibility most of which originate from experimental design or methodology 1,2 such as insufficient proteome coverage and low workflow precision 3, 4 . It is also difficult to obtain longitudinal samples and perform multidisciplinary studies 1 . However, another significant cause is the biological variability of protein expression and modification [5] [6] [7] [8] . Protein modifications are variable among healthy individuals and diseases further alter the diversity of multiple proteoforms 8 producing dysfunctional or even toxic entities 9, 10 . Therefore, it is illogical to expect that it is possible to produce a reliably usable biomarker from an entire protein family deduced from a few tryptic peptides 11, 12 . This role is more reasonably fulfilled by one or multiple distinct proteoforms.
To identify and quantify specific proteoform biomarkers among the many and varied modifications possible, new experimental ideas and settings are required because the common shotgun and bottom-up approaches are insufficient for this purpose 13 . More suitable for identifying disease specific modifications are comprehensive, unbiased, and precise sample pre-fractionation methods on the protein level 7, 8, 12 , combined with sophisticated data analyses.
We therefore developed an unbiased protein pre-fractionation workflow using non-denaturing multidimensional chromatography. We adapted the workflow for the proteomic analysis of body fluids without any depletion. This workflow therefore allows the characterization of the entire proteome. The combination of parallel liquid handling, microplate format, and automation ensures maximum velocity, precision and reproducibility 14 . Moreover, the workflow inherently produces highly characteristic sub-fractions. This thereby preserves information on the native molecular weight (Mw, indicating complex formation, large posttranslational modifications (PTM), and fragmentation), charge (-PTM and conformation), and lectin affinity (-major types of glycans). The immune reactivity and biological activities of the proteoforms can also be analyzed in our native sub-fractions when required 15 . Such information is beneficial for identifying specific proteoform biomarkers as well as for their validation.
As expected, we showed that the majority of plasma proteins appear in multiple chromatographic clusters 7, 16, 17 . It is necessary to determine the probable reasons for this heterogeneity in order to identify biomarkers that are highly specific for particular diseases. A principal reason is that different proteoforms are characterized by different splice variants and PTM. In addition, however, it is necessary to consider the role of fragmentation and of complex formation with proteins and metabolites. Since albumin is the dominant plasma protein and is not known to be glycosylated or otherwise functionally modified but might be altered in the body by various processes 18 , we used it as an example for characterizing the capabilities of our workflow. To provide proof of principle, we searched albumin heterogeneity for various PTM.
Results
characteristics of the separation procedure. Our method orthogonally combined size exclusion chromatography (SEC, first dimension, 1D), followed by anion exchange (AEC, 2D) and, optionally, lectin affinity (LAC, 3D) chromatography ( Fig. 1 ). After serial 1D-fractionation, all further procedures were performed in microplate format. Beginning with 2D-fractionation, parallelization and automation was achieved for separation, preparation and analyses. Our automated workstation ( Fig. 2a ) enabled automated multichannel pipetting and robotic handling of microplates, reservoirs, and micro-column arrays, previously visualized by video 16 . For all fractionation processes, hit picking and analytics were controlled by adapted software packages. We developed several tools to maximize compatibility, throughput, recovery and precision of the preparation steps. We based protein recoveries from the corresponding load into liquid sub-fractions on UV measurements. native size exclusion chromatography enabled high protein input. Our first step, 1D-SEC, was characterized by the greatest reproducibility for reference peaks of UV-absorbing material ( Supplementary Fig. 1 , Table 1 ) regarding height and retention (elution volume). This initial step determined the scale of protein input Figure 1 . Scheme of the workflow. Blue: methods, processes and some characteristics; orange: potential information derived from the location of identified constituents and from additional analyses of sub-fractions.
(from 2 to more than 100 mg) and the expected range of molecular weight (from 2 to 1000 kDa). As expected, the recovery of UV-absorbing material was ~100%. Thus, the entire protein content (>30 kDa) of blood plasma (mean 93.7, SD 2.7% of the UV-absorbing material, cf. Supplementary Fig. 1 ) was completely separated from the intrinsic low molecular weight peptidome (<6 kDa).
Micro-column arrays provided truly parallel, automated and precise fractionation. No com-
mercially available micro-columns for parallelized chromatography met all the requirements for volumes of 1Dand 2D-fractions, binding capacity, compatibility to 384-well microplates, free-flow elution of tunable elution rate, and precision. Therefore, we had to develop and optimize these tools ourselves. We made our own single columns and column arrays ( Fig. 2d ,j). We used empty SPE cartridges for AEC ( Fig. 2h ) and modified pipette tips for LAC ( Fig. 2i ). AEC runs over 100 µL Toyopearl DEAE-650M (Tosoh Bioscience GmbH, Stuttgart, Germany) and LAC over 70 µL Toyopearl AF-Tresyl 650 M (Tosoh Bioscience GmbH) modified with Concanavalin A (ConA, Sigma-Aldrich, C7275) and wheat germ agglutinin (WGA, Sigma-Aldrich, L9640) 14 . UV-absorbing material was recovered at mean 97.1, SD 11.2% with 3.8% CV after 2D fractionation and mean 88.8, SD 3.6% and 5.1% CV after 3D-fractionation 14 . parallel medium exchange by dialysis reliably produced compatibility with subsequent steps. Dialysis ensured compatibility of 1D-sub-fractions with 2D-AEC. It also removed sugars from 3D-sub-fractions and superfluous reagents from all sub-fractions after denaturation and modification prior to tryptic digest and mass spectrometry (MS). To perform medium exchange, we selected parallelized microdialysis and developed various tools ( Fig. 3 ) 19, 20, 14, 21 suitable for ensuring comprehensiveness and non-selectivity (see also https://www.scienova.com). For this method, only liquid handling was required, so guaranteeing high through-put, automation, and high precision. With the tool in Fig. 3a we routinely prepared 1D-sub-fractions for 2D-AEC. All tools achieved high protein recovery determined applying model proteins (bovine serum albumin (BSA), hemoglobin) and sample volumes of 100 µL recoveries (e.g. mean 93.1, SD 1.3% 21 (tool in Fig. 3b ); mean 100.8, SD 0.01% 19 (tool in Fig. 3c) ). Moreover, the tool in Fig. 3c was applicable to a wide range of sample volumes (from 10 to nearly 600 µL) with similar quality characteristics and it can be processed with various multichannel pipettes, including robots.
our automated platform executed laborious repeated cycles of parallel chromatography. We iteratively developed our automated platform 14, 22 . With its current design ( Fig. 2a ) and its constituent tools (Figs 2 and 3), we were able to parallel process four samples through 2D-fractionation within three days (successive 1D SEC: two days including column calibration; parallel 2D AEC: one day including the medium exchange needed before AEC). Additional time was required for 3D-separation, tryptic digest, and MS. Our fractionation applied repeated process cycles with the selection of the target microplate, precise pipetting of fractions and of elution solvents on micro-columns, followed by complete flow-through and read out. 1D-sub-fractions were retrieved by the first liquid handler ( Fig. 2a ). The column arrays were adjusted to one partition of a microplate (Fig. 2d ). The flow-through followed gravity without any support after a short initial pneumatic push (video in 16 ). Elution solvents produced a stepwise gradient with increasing ionic strength 14 (cf. Fig. 4c ). From each 1D-fraction, four 2D-fractions were collected within one microplate. All successively filled microplates were instantly and automatically read ( Fig. 2e) , sealed, and transferred to the refrigerator (Fig. 2f ). The platform can also, in principle, perform LAC. Picking and reformatting of fractions for subsequent preparation or MS was performed by the second liquid handler with 8 independent channels ( Fig. 2g ).
Examples of verified biomarkers. Applications of our methods showed versatility and high protein yield
of plasma proteins from humans, cattle, goats, dogs and mice, and from human CSF (cf. Supplementary Tab. 1). The number of proteins identified in human samples is similar to that of current studies applying various proteomic approaches (e.g. [23] [24] [25] ). For example, from pooled human CSF, we were able to identify 5185 non-redundant proteins supported by ≥1 peptides and 1691 by ≥2 peptides. We also applied our method to the search for biomarkers of severe inflammation or sepsis, renal failure, Alport syndrome 17,26-28 , and psoriasis 16 . In these searches, we obtained several candidate markers with significantly altered protein concentrations inferred from MS data. We validated several of these using immunoassays.
It must be noted that we consistently identified not only one but several chromatographic clusters for the majority of altered proteins, some of which demonstrated opposite directions of alteration. Sometimes we were unable to verify the main alteration of such biomarker candidates by commercial ELISA 6,7 rather than one out of a minor cluster 16 . We are currently searching for the probable reasons for this heterogeneity of our biomarkers. We were able, using the facilities of the Proteome Discoverer © (see Online Methods), to uncover several interesting PTM for a variety of clusters of plasma proteins (patent sensitive data not shown). Below, we discuss our results for albumin, using it as an example of a typical eukaryotic protein. www.nature.com/scientificreports www.nature.com/scientificreports /   2D  0  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  Mr  1D sample 25 mM NaCl 40 mM NaCl 50 mM NaCl 75 mM NaCl 100 mM NaCl (kDa) 41 0,01 0,24 0,34 0,32 0,07 0,02 0,02 0,02 0,07 0,03 0,02 0,01 0,03 0,03 0,02 0,02 0,10 0,08 0,06 0,07 0,26 0,13 0,07 278,55 42 0,04 0,39 0,54 0,50 0,11 0,03 0,02 0,02 0,07 0,03 0,02 0,02 0,03 0,02 0,02 0,02 0,10 0,08 0,06 0,08 0,27 0,14 0,08 264,67 43 0,04 0,61 0,83 0,77 0,17 0,04 0,03 0,03 0,09 0,04 0,02 0,02 0,03 0,02 0,02 0,02 0,10 0,08 0,06 0,08 0,26 0,14 0,08 251,48 44 0,05 0,95 1,18 1,10 0,20 0,04 0,03 0,04 0,11 0,05 0,03 0,02 0,03 0,02 0,02 0,02 0,11 0,08 0,07 0,08 0,29 0,14 0,09 238,95 45 0,10 1,26 1,54 1,43 0,32 0,05 0,03 0,03 0,11 0,05 0,03 0,02 0,04 0,03 0,02 0,02 0,12 0,09 0,08 0,10 0,30 0,15 0,09 227,04 46 0,12 1,51 1,79 1,69 0,33 0,06 0,04 0,05 0,14 0,06 0,03 0,02 0,04 0,03 0,02 0,03 0,14 0,10 0,08 0,10 0,33 0,16 0,10 215,72 47 0,14 1,63 1,91 1,80 0,39 0,07 0,05 0,05 0,14 0,06 0,04 0,03 0,05 0,03 0,03 0,03 0,14 0,10 0,09 0,11 0,33 0,18 0,12 204,97 48 0,12 1,54 1,82 1,75 0,35 0,06 0,04 0,05 0,15 0,06 0,03 0,03 0,05 0,04 0,03 0,03 0,13 0,09 0,08 0,10 0,32 0,17 0,10 194,76 49 0,12 1,59 1,79 1,70 0,32 0,05 0,04 0,04 0,13 0,05 0,03 0,03 0,04 0,03 0,03 0,03 0,12 0,09 0,07 0,09 0,32 0,16 0,10 185,05 50 0,08 1,39 1,64 1,59 0,27 0,05 0,04 0,04 0,12 0,05 0,03 0,02 0,04 0,03 0,02 0,02 0,11 0,08 0,06 0,08 0,28 0,16 0,09 175,83 51 0,07 1,16 1,40 1,33 0,21 0,04 0,03 0,03 0,11 0,04 0,02 0,02 0,04 0,03 0,02 0,02 0,09 0,06 0,05 0,06 0,25 0,13 0,07 167,07 52 0,06 0,85 1,03 0,99 0,17 0,03 0,02 0,03 0,11 0,04 0,02 0,02 0,04 0,03 0,02 0,02 0,09 0,06 0,05 0,06 0,22 0,13 0,07 158,74 53 0,03 0,59 0,79 0,74 0,13 0,03 0,02 0,03 0,10 0,03 0,02 0,01 0,04 0,03 0,02 0,02 0,08 0,06 0,05 0,06 0,20 0,11 0,06 150,83 54 0,02 0,40 0,51 0,51 0,10 0,03 0,03 0,03 0,12 0,04 0,02 0,02 0,04 0,03 0,03 0,02 0,09 0,06 0,05 0,06 0,20 0,12 0,06 143,32 55 0,02 0,25 0,38 0,37 0,08 0,03 0,03 0,05 0,16 0,05 0,03 0,02 0,05 0,04 0,03 0,03 0,11 0,07 0,06 0,06 0,19 0,10 0,05 136,18 56 0,01 0,16 0,30 0,32 0,08 0,04 0,04 0,06 0,23 0,06 0,03 0,02 0,06 0,05 0,04 0,03 0,14 0,09 0,07 0,06 0,18 0,10 0,05 129,39 57 0,00 0,13 0,30 0,33 0,10 0,05 0,06 0,10 0,34 0,08 0,04 0,03 0,07 0,05 0,04 0,04 0,19 0,11 0,07 0,07 0,19 0,10 0,05 122,94 58 0,01 0,15 0,37 0,42 0,13 0,08 0,08 0,12 0,42 0,11 0,04 0,03 0,08 0,06 0,05 0,05 0,27 0,14 0,09 0,07 0,22 0,11 0,06 116,82 59 0,00 0,11 0,43 0,53 0,18 0,11 0,11 0,19 0,56 0,11 0,06 0,03 0,09 0,09 0,09 0,10 0,38 0,14 0,09 0,08 0,25 0,12 0,05 110,99 60 0,00 0,13 0,51 0,64 0,24 0,13 0,14 0,24 0,53 0,14 0,07 0,07 0,20 0,17 0,12 0,14 0,40 0,15 0,10 0,10 0,25 0,11 0,05 105,46 61 -0,01 0,13 0 ,64 0 ,81 0 ,29 0 ,16 0 ,15 0 ,22 0 ,61 0 ,38 0 ,17 0 ,13 0 ,27 0 ,20 0 ,13 0 ,14 0 ,43 0 ,18 0 ,12 0 ,12 0 ,27 0 ,13 0 ,06 100,21 62 0,00 0,14 0,64 0,89 0,32 0,17 0,15 0,21 1,03 0,58 0,20 0,13 0,29 0,20 0,13 0,13 0,47 0,19 0,12 0,11 0,29 0,12 0,06 95,21 63 0,00 0,16 0,75 1,13 0,42 0,19 0,18 0,37 1,54 0,64 0,21 0,14 0,30 0,21 0,15 0,14 0,50 0,24 0,15 0,13 0,32 0,12 0,12 90,47 64 0,00 0,22 0,96 1,48 0,59 0,22 0,26 0,60 1,60 0,63 0,20 0,14 0,29 0,20 0,13 0,14 0,49 0,23 0,15 0,13 0,32 0,14 0,07 85,96 65 0,00 0,13 0,82 1,65 0,70 0,24 0,30 0,75 1,70 0,63 0,19 0,13 0,30 0,21 0,14 0,14 0,53 0,24 0,16 0,14 0,33 0,15 0,08 81,68 66 0,00 0,12 1,08 2,09 0,91 0,33 0,46 0,85 1,79 0,63 0,22 0,13 0,30 0,21 0,14 0,14 0,55 0,25 0,16 0,15 0,36 0,16 0,08 77,61 67 -0,01 0,11 1 ,39 2,18 1,19 0,27 0,24 0,88 1,73 0,61 0,18 0,13 0,29 0,20 0,13 0,12 0,56 0,24 0,16 0,14 0,34 0,16 0,07 73,74 68 -0,01 0,11 1 ,41 2,18 0,86 0,35 0,45 0,90 1,72 0,67 0,22 0,14 0,30 0,22 0,14 0,13 0,53 0,24 0,15 0,13 0,34 0,16 0,08 70,06 69 -0,01 0,09 1 ,22 2,09 0,90 0,34 0,47 0,85 1,69 0,60 0,19 0,13 0,28 0,20 0,13 0,14 0,51 0,23 0,14 0,13 0,32 0,15 0,07 66,57 70 0,00 0,02 0,73 1,95 0,85 0,30 0,45 0,89 1,73 0,68 0,20 0,13 0,30 0,21 0,17 0,15 0,51 0,23 0,15 0,13 0,30 0,16 0,08 63,26 71 0,00 0,03 0,40 1,35 0,58 0,23 0,31 0,57 1,73 0,57 0,21 0,13 0,30 0,22 0,14 0,14 0,50 0,23 0,14 0,11 0,27 0,13 0,07 60,10 72 0,00 0,01 0,16 0,54 0,27 0,14 0,20 0,53 1,55 0,58 0,22 0,14 0,30 0,20 0,14 0,13 0,46 0,19 0,11 0,10 0,23 0,10 0,05 57,11 73 0,00 -0,01 0,06 0,10 0,06 0,03 0,05 0,19 1,38 0,58 0,19 0,13 0,30 0,21 0,14 0,14 0,45 0,17 0,11 0,09 0,19 0,08 0,05 54,26 74 0,00 -0,01 0,03 0 ,04 0 ,02 0 ,02 0 ,02 0 ,03 0 ,76 0 ,54 0 ,19 0 ,13 0,30 0,20 0,14 0,14 0,45 0,16 0,10 0,08 0,16 0,07 0,04 51,56 75 -0,01 -0,02 0,01 0,02 0,02 0,01 0,01 0,02 0,27 0,36 0,18 0,13 0,29 0,20 0,14 0,16 0,44 0,16 0,09 0,08 0,13 0,06 0,03 48,99 76 0,00 -0,02 0,00 0 ,01 0 ,01 0 ,01 0 ,01 0 ,02 0 ,09 0 ,08 0 ,07 0 ,06 0,21 0,18 0,12 0,13 0,41 0,14 0,07 0,06 0,11 0,04 0,02 46,55 77 0,00 -0,01 0,00 0 ,00 0 ,01 0 ,01 0 ,00 0 ,01 0 ,03 0 ,02 0 ,01 0 ,01 0 ,04 0 ,03 0 ,04 0 ,05 0 ,27 0 ,12 0 ,06 0 ,05 0 ,07 0 ,02 0 ,01 44,23 78 -0,01 -0,02 -0,01 0,00 0 ,01 0 ,00 0 ,00 0 ,00 0 ,01 0 ,00 0 ,00 0 ,00 0 ,00 0 ,00 0 ,00 0 ,00 0 ,04 0 ,05 0 ,03 0 ,02 0 ,03 0 ,01 0 ,00 42,02 0,00 0,02 0,03 0,04 0,10 0,15 0,20 0,40 0,60 0,80 1,0 2 ,0 mg/ml 0,02 0,03 0,04 0,10 0,15 0,20 0,40 0,60 0,80 1,00 2,0 3 ,0 c Supplementary Fig. 1 ). www.nature.com/scientificreports www.nature.com/scientificreports/ Albumin is a pure protein and not enzymatically modified but showing at least 17 proteoforms in blood plasma from human volunteers. We found albumin consistently highly heterogeneous in all of our blood samples from both patients and healthy control individuals 16, 17, 26, 27 , just as many other plasma proteins are. After 1D-SEC, immune reactive albumin reproducibly separated into three distinct peaks with apparent molecular weights of ~90-95 kDa, ~69-73 kDa, and ~50 kDa ( Fig. 4a,b) . Moreover, the low Mw form showed the strongest decline in patients suffering from sepsis 26 . As many as 17 chromatographic clusters of this protein were produced after 2D-AEC ( Fig. 4c ). We analysed pools of 2D-sub-fractions of each cluster using the Proteome Discoverer © , as indicated by boxes ( Fig. 4c ) (cf. Methods).
Each proteoform of serum albumin showed its own individual number and pattern of modifications. We were, in fact, able to identify several modifications, such as deamidation (R, N, Q), N-glycation (the majority on K, a few also predicted on R and Q), palmitoylation (S, K, T) and palmitoleylation (S, K), myristoylation (K), octanoylation (S, T), decanoylation (S, T), ethylation (E, K), acetylation (H, K, S, T, Y), methylation (D, E, H, I, K, L, N), dimethylation (K, N, R), propionylation (S, K), succinylations (K), carboxylation (K, E, D), carbamoylation (K), carboxymethylation (K), carboxyethylation (K), and phosphorylations (T, S, Y) and guanidylations (K).
To compare the results of different sub-fractions, the number of modified sites was normalized by the total number of identified peptide spectra matched for albumin (PSM) of the same search run. This allowed for a semi-quantitative comparison based on the degree of modification. As expected, the chromatographic clusters and the pools they represented were not uniformly modified. In healthy controls, each cluster possessed its own characteristic pattern of modification ( Supplementary Fig. 2a ). Moreover, in all blood samples, the degree of an assortment of modifications correlated well with the NaCl concentration required for AEC elution with respect to the predicted net charge, at least with the major albumin-containing pools that exhibited the highest PSM and sequence coverage. These modifications were carbamyolation (Fig. 5a) , deamidation (N, Q: Fig. 5b ; R: Fig. 5c ), myristylation (Fig. 5d ), and the number of hexoses linked to K (Fig. 5e ). Carboxymethylation and carboxethylation inversely correlated with AEC elution (Fig. 5i ). Palmitoylation, palmitoleylation, and methylation show maxima in different sub-fractions ( Fig. 5f-h) . Moreover, in healthy controls, the intensity of fluorescence related to the advanced glycation end products (AGE) correlated with the ionic strength ( Supplementary Fig. 6a ) required for elution as well as with carbamoylation and glycation ( Supplementary Fig. 6b,c) .
Albumin clusters in non-diabetic patients suffering from ESRD had a similar modification pattern ( Supplementary Fig. 2b ). Of note is the marked elevation of deamidations (Fig. 5b,c) , phosphorylation, succinylation ( Fig. 5j,k) , as were carbamoylation. This was particularly so in sub-fractions originating from the apparently low Mw 1D-fraction (1D 71, Fig. 5a ). As expected, AGE-fluorescence intensities were much higher in all sub-fractions from patients than from controls ( Supplementary Fig. 6a ). In contrast to the situation in healthy people (see above), in patients most of these values do not correlate either with the number of the same modifications per PSM or with carboxymethylation and methylation ( Supplementary Fig. 6 ).
Serum albumin of dog puppies is also heterogeneous in blood plasma. Plasma from puppies had a similar distribution of sub-fractions containing albumin (P49822, Supplementary Fig. 3 ). The centric Mw was ~6 kDa higher than predicted from the sequence data (Uniprot) as with human albumin. However, because of small volumes, it was not possible to build pools of the residual 2D-fractions. Therefore, we reanalyzed the raw data from single 2D-fractions derived from the centric 1D-fraction 64. These fractions contained several modifications similar to those in human albumin although all to a lower degree: carbamoylation (K) (Fig. 5l ), deamidations (N, Q, R) N-glycation (K), methylation (E, D, H), and carboxymethylation (K) and acetylation (T, S, H, Y)). With the exception of carbamoylation, these modifications show no clear correlation with AEC-elution. In contrast to the case in samples from human adults, there was no palmitoylation, myristoylation, octanoylation or decanoylation. However, some propionylations on S471 were evident. It should be noted that the degree of carbamoylation of 2 sub-fractions was much higher in puppies with preclinical Alport syndrome (bearing the collagen IVα5 mutation) than in healthy controls (Fig. 5l ).
Albumin in human cSf. In contrast to plasma albumin, the main protein peak in CSF has only one centric Mw of ~78 kDa after 1D-SEC which, as in plasma, was distributed over five 2D-AEC elution steps ( Supplementary  Fig. 4 ). After immune quantitation, we were only able to identify a subset of only 4 albumin proteoforms in CSF ( Supplementary Fig. 5 ). These had several modifications, such as carbamoylation (Fig. 5a ), glycation (Fig. 5e ), and methylation ( Fig. 5h) , which were correlated with the expected net charge. Nevertheless, these modifications were rarer than in the corresponding albumin forms from plasma. A few deamidations were present but without correlation with 2D-AEC elution (Fig. 5b,c) . While one octanylation (S478) was always present, there was no carboxymethylation and no carboxyethylation, and only very rare palmitoylation and myristoylation.
Discussion
The precision of sample pre-fractionation and proteome coverage of our workflow allows reliable sample comparison for biomarker search. We were therefore able to validate several biomarker candidates by ELISA 16, 17, 26, 28 . Nevertheless, it was not possible to verify by immune assay some of our other biomarker candidates that appear in one of a multitude of chromatographic clusters 16, 28 . We therefore analyzed the principle and capability of our pre-fractionation in order to determine whether such clusters represent enriched proteoforms varying in, and separated according to, characteristic PTM. To this end we analyzed, as an example, chromatographic clusters of albumin, after 2D-separation. We omitted 3D-separation and the analysis of glycans because albumin is not glycosylated 29 . Although we still used highly variable protein mixtures for PTM search, albumin represented the main component throughout. Within each search run it was possible to identify not only location but also the maximum number of occupied or modified sites. However, it was possible to estimate the rate of modification by normalizing these counts with PSM (i.e. the sum of modified and non-modified identified peptides).
The serum albumin of healthy individuals and patients contains several major modifications attributed to micro heterogeneity (oxidation, glycation and S-nitrosylation) 10, 18, 30 . Nevertheless, information on the extent and distribution of other modifications is rare. There are, though, two major and seven minor fractions identified and partially characterized by IEX/MS starting from Cohn fraction IV 31 . Our native 2D-fractionation method applied to whole blood plasma shows, however, that the complexity is, in fact, much higher. Serum albumin subdivides into at least 17 different parts all of which are modified in multiple ways. Most of the modifications, with the exception of deamidation, glycation and methylation, affect less than one percent of all the peptides identified (PSM). Nevertheless, their cumulative effect on charge and conformation might produce the characteristic sub-fractions observed. Carbamoylation (K), deamidation (N, Q), and glycation (K) lead to the loss of positive charges 32 , produce higher negative net charges, and correlate well with the ionic strength necessary for elution from our AEC matrix. In contrast, we found an inverse relationship for carboxymethylation and carboxyethylation (K), although these modifications introduce additional negative charges (Fig. 5i ). Carboxylations (K, E, D) surprisingly show no relation to AEC elution. It is possible, therefore, that this is because these modifications either form intramolecular complexes, complexes with other plasma proteins, or complexes with divalent metal ions, thereby altering conformation and the interaction with the AEC matrix. Some known modifications of albumin have a strong influence on the structure and function of albumin 18, 33, 34 . All other PTM were present to an even lower degree on various sites and showed no clear relation to AEC-elution. For the first time we identified various acylations of distinct albumin sub-fractions. Although up to 6 fatty acids might bind non-covalently to albumin with high affinity 29, 35 , no covalent lipidation has yet been described in the literature. Nevertheless, Nand O-fatty-acylations occur on intracellular proteins 36 . Moreover, there is some data on acylated functionally active proteins in blood plasma, such as growth hormone 37 and ghrelin 38 . Acylation can be achieved by both, enzymatic and non-enzymatic 37, 39 and seems to be compatible with water solubility when fatty acids are buried within hydrophobic pockets 38 , like the non-covalently bound hydrophobic cargo of albumin. It is conceivable that acylation might promote protein-protein interaction. Moreover, we found no S-palmitoylation 40 (C) probably due to the instability of this bond under DDT reduction before MS 37 . Albumin acylation still requires verification by other means.
In addition, we re-identified a low degree of carbamoylation in healthy individuals in accordance with a previous study 41 as well as its increase (in a sub-set of our albumin fractions) under renal failure. This modification competes with glycation and is raised under diabetes, chronic kidney diseases, and inflammation 41, 42 . Carbamoylation might occur artificially if urea is present in high concentrations (e.g. for denaturation) 43 . This is not true for our method and therefore such an artefact is highly improbable.
Deamidation is a common modification of several proteins occurring spontaneously, both in vivo and in vitro. Non-enzymatic deamidation of Q and N is considered to be both pathological and physiological, increasing protein negative charge, altering conformation, stability, longevity, and function 44 . Although Q is more resistant to deamidation 44 than N (under physiological conditions its half-life is ten times that of N), we identified Q and N deamidations in similar proportions in our albumin fractions (e.g. mean number/PSM in all pools from healthy males: N, 0.0123; Q, 0.0117). Deamidation (N + Q) shows a strong correlation with AEC elution (Fig. 5b) . We cannot exclude, however, that spontaneous N deamidation might be favored to a degree by the conditions of our tryptic digest after protein separation. High pH and temperature, particularly with the use of ammonium bicarbonate, is known to produce this modification 44 . However, because we uniformly applied these conditions to all sub-fractions, the differences identified cannot be explained as artifacts. The degree of R deamidation is higher in ESRD patients than in healthy individuals, but lower than those of Q and N (Fig. 5c ). Deamidation converts R into either ornithine or citrulline 45 thereby altering polarity but not charge. Although this modification can occur spontaneously under alkaline conditions 45 , the sites of deamidation were identical across all analyzed plasma sub-fractions: R264, R343, R542. The degree of oxidation of M correlates well with our AEC elution. Although the oxidation of albumin (C, M) is a common and wide spread reaction 46 particularly as part of the antioxidant activity of albumin 47, 48 and under oxidative stress in renal diseases 49 , we omitted these data, because we are unable to exclude the possibility of some oxidation during sample preparation. In contrast, glycation is unlikely to result from ex vivo reactions 50 , since this non-enzymatic reaction exhibits low binding rate constants and requires high glucose concentration and temperature 51 . This reaction is unlikely in our study as all our samples were frozen quickly in liquid nitrogen. Moreover, after 1D-separation (SEC) the proteins were freed from non-bound sugars. Thus the degree of glycation appears to reflect natural modification.
All PTM were primarily identified as mass alteration of peptides by MS. Although distinct mass alterations might be attributed to different PTM, there is currently no alternative to MS for the majority of the PTM we identified. For partial verification we were able to quantify albumin concentration, glycation, and carbamoylation by the ELISA techniques available. The total albumin immune reactivity correlated well with the MS measure "area" for all the albumin peptides identified ( Supplementary Fig. 7a ) as well as with PSM in the concentration range of the majority of sub-fractions. As expected, PSM values were saturated at high protein concentrations ( Supplementary Fig. 7b ). However, quite surprisingly, neither the degree of glycation or of carbamoylation by MS was correlated with those determined by ELISA ( Supplementary Fig. 7c,d) . The percentages of glycation were similar with both methods; carbamoylation was much lower in ELISA than in MS. This illustrates a difficulty; the MS and ELISA results do not refer to exactly the same items. In contrast to ELISA, the MS determination of hexoses included not only glucose but also other sugars of the same Mw without identifying these other sugars. MS quantifies the number of modified residues, ELISA, however, detected the concentration of modified protein molecules. ELISA therefore probably either detected only some of the modifications or identified them independently of the variation in the number of modified sites per protein molecule. Nevertheless, the percentages of the immune reactive glycated albumin protein correlated well with AEC elution (Supplementary Fig. 7e ) and AGE fluorescence intensities ( Supplementary Fig. 7f ). The percentages were higher in patients than in controls in accordance with 52, 53 . Moreover, the total amount of albumin determined by ELISA in patients was shifted slightly from little modified to greatly modified entities compared to amounts in healthy people ( Supplementary  Fig. 5 ). We were unable to analyze pentosidin formation by our MS equipment, a well-known modification under ESRD 54 . So we tried to quantify this modification by ELISA in order to explain the high AGE fluorescence intensities in samples from patients. However, we were unfortunately unable to do this because our 2D fractions contained protein concentrations at the lowest and most unreliable levels that ELISA is able to detect.
The three apparently different molecular weights of plasma albumin could not be explained by PTM, since MS data does not provide strict stoichiometry. Nevertheless, besides PTM it is also possible that apparently large size proteoforms result from complex formation with members of the "albuminome" 55 . We unfortunately cannot discriminate complex formation from co-elution, since non-covalent, low affinity complexes might be dissolved after 2D-AEC. For example, we were, in fact, able to identify α-1 antitrypsin and vitamin D-binding protein in some sub-fractions co-eluting with albumin ( Supplementary Fig. S2a,b) which are well-known to ligate with albumin 56, 57 . In healthy individuals, we can exclude the possibility that huge fragmentation and truncation produced low-molecular weight forms because the sequence coverages of the apparently low and high Mw forms are practically identical. It is probable that different strengths of the interaction with the SEC matrix due to different sets of PTM 58 might be attributed to different protein conformations producing low apparent Mws. We are not able to exclude nicked but adhering fragments. By such modification no altered Mw might be produced rather than an altered conformation. The allocation of albumin after 2D-AEC unexpectedly does not always follow the estimated net charge (cf. carboxylation and carboxymethylation). Moreover, the distribution into identical sub-fractions from patients and from healthy individuals occurs with different degrees of modification (e.g. deamidation, carbamoylation). Hence, the assignment of proteoforms might depend only in part on net charge but also on different conformations, probably due to a certain modification threshold, pattern or, even, an as yet unrecognized modification.
CSF albumin is heterogeneous and also, to a degree, physicochemically different from that in plasma 59 . Applying our workflow, we were only able to identify only 4 clusters with different degrees of PTM. The degree of carbamoylation ( Fig. 5a ), glycation ( Fig. 5e ) and methylation (Fig. 5h ) is much lower than in plasma. The degree of acylation is so low that CSF albumin can be considered non-acylated. It is possible to explain these differences between CSF albumin and plasma albumin either by a selective transfer of only a subset of modified proteoforms from plasma into CSF 60 , by the absence of complex formation with the plasma "albuminome" or, probably, by synthesis within the central nervous system.
In contrast to Multiomics by SIMPLEX, the simultaneous profiling of proteins, lipids and other metabolites in initially denatured samples 61 , our method provides a native proteoform-resolved measurement addressing PTM and compound adducts. Thus, the separation principle of our workflow, combined with its quality characteristics, reproducibly produces highly distinctive protein fractions. As we demonstrated by example, our workflow is optimally suitable for the detection and analysis of differentially regulated proteoforms. Major proteins, like albumin, can be analyzed directly in sub-fractions from blood plasma as well as from CSF. Some of the albumin PTM we identified coincide with those found elsewhere (see above). Moreover, our precise micro-separation can be used for the native preparation of sufficient amounts of selected minor constituents directly from pre-analyzed sub-fractions. This serves as a prerequisite for their final enrichment and subsequent more reliable characterization by targeted MS or other analytical techniques so as to provide true biomarker candidates and antigens for the development of highly PTM selective immunological assays.
Methods plasma samples. We included 4 randomly selected healthy human volunteers (mean age 33.5, SD 5.9 years) and 4 patients (54.5 SD 2.3) with end stage renal failure but without diabetes mellitus. Both groups contained 2 males and 2 females. Nine milliliters of blood were collected by venipuncture into EDTA containers (02.1066.001, Sarstedt Nümbrecht, Germany) and centrifuged at 1500 g * 10 min at room temperature no longer than 30 min after withdrawal 16 . Samples from patients were identically obtained immediately before hemodialysis treatment. Dog samples were collected from a colony of dogs with X-linked hereditary nephropathy. These dogs have a naturally occurring, 10 base pair deletion in the gene encoding the α5 chain of type IV collagen. Samples were Table 1 . Reproducibility of 1D-SEC. Molecular weights were determined according column calibration 14 .
For designation of peaks (maxima, I-V) and valleys (minima, 1, 2) see Supplementary Fig. 1 . There were three measuring points around each maximum/minimum of each run (15 runs). The means and CV thus covered 45 data points (the same data as in Supplementary Fig. 1 ).
Scientific RepoRtS | (2019) 9:11733 | https://doi.org/10.1038/s41598-019-48278-y www.nature.com/scientificreports www.nature.com/scientificreports/ collected from 7-week old unaffected male and female, carrier female, and affected male siblings by jugular venipuncture. Blood was placed into a glass EDTA tube which was immediately placed on ice and centrifuged within 30 minutes of collection at 1500 g * 10 min at 4 °C. After centrifugation, the tubes were placed on ice, and plasma was removed, avoiding the buffy coat interface. The plasma was maintained on ice until frozen at −80 °C within 2 hours of initial blood collection. The samples were stored at −80 °C for two to three weeks before being shipped on dry ice and transferred to long-term liquid nitrogen storage. No freeze-thaw cycle was allowed. Human samples were collected in accordance with ethics agreement 4829-06/2016 (JUH Jena). The informed consent of all participants was obtained. Dog samples were collected in accordance with ethics agreements AUP IACUC 2013-0028 and 2016_0017 (TAMU Texas). The study protocol was reviewed and approved by the Texas A&M University Institutional Animal Care and Use Committee. cSf samples. We used CSF sample from 26 patients with neurological symptoms. CSF samples were collected in accordance to the ethical agreement 3633-11/2012 (JUH Jena). From all participants 12 mL of CSF were collected in polypropylene tubes (Greiner Bio-One 115261) following standard protocol (of the 12, the first 4 mL were used for laboratory measurements). The samples were kept on ice and immediately centrifuged at the bed side for 10 min. at room temperature (3500 g). Supernatants were aliquoted into cryovials (VWR, 479-1237), shock frozen in liquid nitrogen and stored at −150 °C. The CSF samples were characterized using key laboratory parameters. For MS analysis we used only samples without either blood contamination or blood-brain barrier disturbance. We assessed blood contamination by visual inspection for erythrocyte sediment and barrier disturbance by checking for erythrocytes, total protein, cell count and CSF:serum albumin ratio). To ensure adequate amounts of protein for analysis we created 3 mixtures. Each mixture was made up of equal volumes of CSF samples from 7-10 individuals. These pools were concentrated ~70-95-fold by ultrafiltration (AMICON ™ Ultra, MWCO 3 kDa, Merck Millipore), followed by 2D fractionation as described below.
Sample preparation. Pre-fractionation of blood samples was performed according to an existing detailed method for human plasma and serum 14, 16, 17 . Briefly, we used a 16/60 Highload Superdex TM 200 column and an Äkta purifier (GE-Healthcare, Munich, Germany) and an automated workstation (laboratory setting, Analytik Jena AG, Fig. 2 ) for 1D-SEC and 2D-AEC. Initial 1D-SEC fractionation produced 96 1D-fractions of different native molecular weight from about 1 mL plasma. Subsequent 2D-AEC on arrays (Fig. 2d ) of self-made microcolumns (Fig. 2h ) separated each 1D-fraction into 43 2D-sub-fractions by applying a stepwise elution protocol 14 . Human plasma was separated individually. Clusters of albumin containing 2D-fractions of human plasma samples were pooled (Fig. 4c) . Mass spectrometry and PTM search. We performed tryptic digest and MS as previously described 14, 16 . Briefly, the separation of tryptic peptides prior to mass spectrometry was performed on a Hypersil Gold UHPLC column (1.9 µm, 50 × 1.0 mm) using an Accela 1250 UHPLC system (both Thermo Fisher Scientific, USA) using binary gradient elution of the mobile phase. This gradient involved 0.1% formic acid in (A) water and in (B) acetonitrile at a flow rate of 150 µL min-1, throughout (0-1 min 5% B, 21 min 30% B, 24 min 40% B, 25 min 90% B, 25.1-26 min 90% B, 26.1-30 min 5% B). Tandem mass spectrometry (MS/MS) measurements were carried out on an LTQ Orbitrap Discovery (Thermo Fisher Scientific, USA) by positive heated electrospray ionization (H-ESI) at a vaporizer temperature of 200 °C. Sheath gas flow (30.0) and auxiliary gas flow (10.0) were used to dry the ionspray. The ionization voltage was set to 4.5 kV and the temperature of the ion transfer tube to 275 °C. The MS/MS system was operated in data-dependent TOP10 mode using 1 microscan. For this purpose, ions were monitored in the LTQ ion trap in full scan centroid mode at m/z 350-1700. The ten most intense ions were run through collision-induced dissociation for further orbitrap high resolution (30,000) analysis (profile data type). Wideband activation was used. The automatic gain control target value for the Orbitrap mass analyzer in full scan mode was 1.0 × 106. The LC-MS/MS was operated via the graphical interface of the Xcalibur software 2.1. Fractions from blood plasma and CSF were run in duplicate and triplicate followed by a blank (water) to avoid carryover. For quality control, a digested transferrin (human (Holo), SERVA Electrophoresis GmbH, 36756, 50 µg mL-1) was analysed four times per microplate.
We considered identical chromatographic 2D-sub-fractions (identical 1D-and 2D-location) to contain identical proteoforms of albumin due to their identical physicochemical properties. Because of this, we were able to combine, when equally pre-fractionated, counts of the PTM of proteins of identical 1D-and 2D-location but from different runs. We built up to 17 pools from 2D-subfractions of each plasma sample containing the major parts of visible albumin clusters. Due to slight differences in pooling of 2D-sub-fractions from healthy individuals, we processed the data sets from the 2 females separately from those of the two males. Although the samples were www.nature.com/scientificreports www.nature.com/scientificreports/ processed apart, we combined the data from all 4 patients under hemodialysis (2 females and 2 males) by taking the mean values. These values we then compared with the identically obtained data from the 2 healthy male individuals. CSF and dog plasma albumin were analyzed in MS data of 2D-fractions of known major albumin content without pooling thereby reanalyzing the MS raw data from human CSF and dogs (still unpublished data) from other studies. The search for PTM ran successively using Proteome Discoverer © 1.3 (Thermo) with no more than three dynamic modification types per run. We considered only highly confident database matches. The following dynamic modifications of amino acids were analyzed: oxidation (M), palmitoyl (K, S, T), palmitoleyl (S, T), myristoyl (K), octanoyl (S, T), decanoyl (S, T), deamidation (N, Q, R), carboxy (D, E, K, W), carboxymethyl (K, W), carboxyethyl (K), carbamoyl (K, M, R), hexose (K, N, R, T, W, Y), acetyl (H, K, S, T, Y), ethyl (E, K), dimethyl (K, N, R), propionyl (K, S), methyl (D, E, H, I, K, L, N), phosphoryl (S, T, Y), and succinyl (K). Multi reports of the related replicates were utilized.
